Company Overview
Company Type: Private Company
Website: www.rippletherapeutics.com
Number of Employees: -
Year Founded: 2019
Total Amount Raised (CAD mm)†: 25.00
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Ripple Therapeutics Corporation, a clinical stage company, develops and delivers drugs for ophthalmic therapeutics. The company offers IBE-814 IVT, a degradable intravitreal dexamethasone prodrug implant targeting DME, RVO, and NIU indications. It also manufactures drug delivery systems and a library of prodrugs polymer-like properties from different active pharmaceutical ingredients, and local sustained drug delivery products. Ripple Therapeutics Corporation was incorporated in 2019 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Reeves, Thomas P.
Co-Founder, President & CEO
Garner, Defne 
Co-Founder & VP of Finance
Naimark, Wendy 
Co-Founder & CTO
Parrag, Ian 
Co-Founder and Director of R&D
Sevigne, Fraidianie 
Vice President of Operations
Fotheringham, Julie 
Vice President of Marketing, People & Culture

Key Board Members
Name
Title
Ahmed, Iqbal Ike K.
Member of Medical Advisory Board
Asrani, Sanjay G.
Member of Medical Advisory Board
Benton, Susan K.
Director
Boyer, David S.
Member of Medical Advisory Board
Francou, Colin 
Director
Kuppermann, Baruch D.
Member of Medical Advisory Board
Lin, Sandra Beach
Director
Lowenstein, Anat 
Member of Medical Advisory Board
Madsen, Dion 
Director
Reichel, Elias 
Member of Medical Advisory Board
Samuelson, Thomas 
Member of Medical Advisory Board
Sharma, Sumit 
Member of Medical Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
MaRS Center South Tower 101 College Street Suite 300 | Toronto, ON | M5G 1L7 | Canada
Phone: 416-673-8170   Fax: 416-977-1329

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
BDC Capital Inc.
Jan-14-2020
Minority
-
Series A
Thea Open Innovation
Jan-14-2020
Unknown
-
Series A


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-14-2020
-
Private Placement
Target
Ripple Therapeutics Corporation
BDC Capital Inc.,Thea Open Innovation

19.13
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-19-2023
Company Conference Presentations
Ripple Therapeutics Corporation Presents at American Drug Delivery & Formulation (DDF) Summit 2023, Sep-19-2023 12:15 PM
May-24-2023
Company Conference Presentations
Ripple Therapeutics Corporation Presents at 2023 CSPS Annual Symposium, May-24-2023 12:30 PM
Jan-09-2023
Company Conference Presentations
Ripple Therapeutics Corporation Presents at BIO Partnering at JPM 2023, Jan-09-2023
Dec-03-2022
Company Conference Presentations
Ripple Therapeutics Corporation Presents at Ophthalmology Innovation Summit, Dec-03-2022 11:40 AM
Jul-13-2022
Company Conference Presentations
Ripple Therapeutics Corporation Presents at 2022 OIS Retina Innovation Summit, Jul-13-2022 08:50 AM


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 09:06 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
23
GlobalData

Sep 15, 2023 07:46 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp - Medical Devices Product Pipeline Summary
Reports
26
GlobalData

Sep 14, 2023 09:27 PM
Ripple Therapeutics Corporation
Ripple therapeutics Corp
Reports
44
GlobalData

Jun 16, 2023 07:54 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp
Reports
44
GlobalData

Jun 09, 2023 09:39 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp - Medical Devices Product Pipeline Summary
Reports
26
GlobalData

Jun 09, 2023 01:56 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
23
GlobalData

Mar 15, 2023 03:10 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp
Reports
45
GlobalData

Mar 10, 2023 04:57 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
24
GlobalData

Mar 10, 2023 02:24 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp - Medical Devices Product Pipeline Summary
Reports
26
GlobalData

Dec 14, 2022 03:56 AM
Ripple Therapeutics Corporation
Ripple therapeutics Corp
Reports
45


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Ahmed, Iqbal Ike K.
Member of Medical Advisory Board
416-673-8170
416-977-1329

Asrani, Sanjay G.
Member of Medical Advisory Board
416-673-8170
416-977-1329

Benton, Susan K.
Director
416-673-8170
416-977-1329

Boyer, David S.
Member of Medical Advisory Board
416-673-8170
416-977-1329

Francou, Colin 
Director
416-673-8170
416-977-1329

Kuppermann, Baruch D.
Member of Medical Advisory Board
416-673-8170
416-977-1329

Lin, Sandra Beach
Director
416-673-8170
416-977-1329

Lowenstein, Anat 
Member of Medical Advisory Board
416-673-8170
416-977-1329

Madsen, Dion 
Director
416-673-8170
416-977-1329

Reichel, Elias 
Member of Medical Advisory Board
416-673-8170
416-977-1329

Samuelson, Thomas 
Member of Medical Advisory Board
416-673-8170
416-977-1329

Sharma, Sumit 
Member of Medical Advisory Board
416-673-8170
416-977-1329

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Reeves, Thomas P.
Co-Founder, President & CEO
416-673-8170
416-977-1329

Garner, Defne 
Co-Founder & VP of Finance
416-673-8170
416-977-1329

Naimark, Wendy 
Co-Founder & CTO
416-673-8170
416-977-1329

Parrag, Ian 
Co-Founder and Director of R&D
416-673-8170
416-977-1329

Sevigne, Fraidianie 
Vice President of Operations
416-673-8170
416-977-1329

Fotheringham, Julie 
Vice President of Marketing, People & Culture
416-673-8170
416-977-1329

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
